Norinchukin Bank The Acquires 21,286 Shares of STERIS plc (NYSE:STE)

Norinchukin Bank The lifted its stake in shares of STERIS plc (NYSE:STEGet Rating) by 15.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 156,668 shares of the medical equipment provider’s stock after buying an additional 21,286 shares during the quarter. Norinchukin Bank The owned about 0.16% of STERIS worth $38,134,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Morgan Stanley grew its stake in STERIS by 222.2% in the second quarter. Morgan Stanley now owns 414,842 shares of the medical equipment provider’s stock valued at $85,581,000 after acquiring an additional 286,093 shares during the period. JustInvest LLC lifted its position in shares of STERIS by 21.7% in the 3rd quarter. JustInvest LLC now owns 1,256 shares of the medical equipment provider’s stock worth $257,000 after purchasing an additional 224 shares during the period. Commerce Bank grew its position in STERIS by 13.8% during the 3rd quarter. Commerce Bank now owns 4,798 shares of the medical equipment provider’s stock valued at $980,000 after purchasing an additional 580 shares during the last quarter. M&G Investment Management Ltd. boosted its stake in shares of STERIS by 16.3% in the 3rd quarter. M&G Investment Management Ltd. now owns 5,908 shares of the medical equipment provider’s stock worth $1,205,000 after buying an additional 829 shares during the last quarter. Finally, First Horizon Advisors Inc. raised its holdings in STERIS by 42.9% during the third quarter. First Horizon Advisors Inc. now owns 730 shares of the medical equipment provider’s stock valued at $122,000 after acquiring an additional 219 shares during the period. Institutional investors and hedge funds own 90.88% of the company’s stock.

STE stock traded up $5.82 during midday trading on Thursday, hitting $218.39. The stock had a trading volume of 655,859 shares, compared to its average volume of 487,711. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.13 and a quick ratio of 1.47. The business has a 50-day moving average of $235.42 and a two-hundred day moving average of $232.72. STERIS plc has a 52-week low of $188.10 and a 52-week high of $255.93. The firm has a market cap of $21.87 billion, a price-to-earnings ratio of 74.74 and a beta of 0.67.

STERIS (NYSE:STEGet Rating) last posted its earnings results on Tuesday, February 8th. The medical equipment provider reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $1.95 by $0.17. The firm had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.20 billion. STERIS had a return on equity of 12.08% and a net margin of 6.57%. The company’s quarterly revenue was up 48.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.73 EPS. Research analysts predict that STERIS plc will post 7.89 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 28th. Investors of record on Tuesday, June 14th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend is Monday, June 13th. STERIS’s payout ratio is 59.52%.

A number of analysts have recently weighed in on STE shares. Wolfe Research began coverage on shares of STERIS in a report on Tuesday, April 5th. They issued an “outperform” rating and a $275.00 price target on the stock. JMP Securities upped their price objective on shares of STERIS from $250.00 to $270.00 and gave the stock a “market outperform” rating in a research report on Monday, February 14th. StockNews.com assumed coverage on shares of STERIS in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Needham & Company LLC raised their target price on STERIS from $254.00 to $263.00 and gave the company a “buy” rating in a report on Thursday, February 10th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, STERIS currently has an average rating of “Buy” and a consensus price target of $261.14.

In related news, CAO Karen L. Burton sold 2,600 shares of STERIS stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $232.61, for a total transaction of $604,786.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Karen L. Burton sold 4,000 shares of STERIS stock in a transaction on Tuesday, March 29th. The stock was sold at an average price of $246.00, for a total transaction of $984,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,600 shares of company stock valued at $5,632,626. 1.14% of the stock is owned by company insiders.

STERIS Profile (Get Rating)

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Recommended Stories

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.